April 2, 2019 – A hearing has been scheduled for May 31, 2019 by the Federal Drug Administration (FDA) to help inform the agency on the best way to proceed with oversight. The hearing was originally announced in February 2019 even though Gottlieb had previously indicated it would be in April of this year. The hearing was filed in the Federal Register today and scheduled to be published tomorrow, April 3rd.
“The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products,” the FDA said in a statement. “FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.”
- The hearing will be May 31, 2019, from 8 a.m. to 6 p.m.
- Submit requests to make oral presentations and comments at the public hearing by May 10, 2019.
- Electronic or written comments will be accepted until July 2, 2019.
- Location: FDA White Oak Campus,10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993